Enlivex (ENLV) AI Stock Analysis

• Market Cap: $229.43M
• Dividend Yield: N/A
• Average Volume (3M): 182.02K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.05
• Revenue Growth: N/A
• EPS Growth: 46.09%
• Country: US
• Employees: 71
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 237,381,500
• 10 Day Avg. Volume: 216,695
• 30 Day Avg. Volume: 182,016
• PEG Ratio: 0.03
• Price to Book (P/B): 1.02
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.83
• Enterprise Value/Market Cap: 0.01
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -9.90
• Enterprise Value/Ebitda: -0.21
• 1Y Price Target: $13.00
• Price Target Upside: 1240.21% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $0.88 ▼(-9.48% Downside)

The score is primarily constrained by weak financial performance (no revenue, ongoing losses, and negative free cash flow), partially offset by low leverage on the balance sheet. Technicals are mixed with a short-term bounce but a broader downtrend, and valuation is not supportive given negative earnings and no dividend yield.

Positive Factors

Product Development

Positive Phase IIa trial results for Allocetra in knee osteoarthritis highlight promising product development, indicating potential for future market entry and addressing unmet medical needs.

Strategic Partnerships

Strategic alliances with pharmaceutical firms provide financial support for trials and research, enhancing Enlivex's ability to advance its therapies and potentially secure future revenue streams.

Low Debt Levels

Low leverage offers financial flexibility, allowing Enlivex to focus resources on R&D and strategic initiatives without the burden of high interest obligations.

Negative Factors

Cash Flow Challenges

Persistent negative cash flow from operations highlights financial strain, risking long-term sustainability and limiting the company's ability to fund ongoing R&D without external financing.

Lack of Revenue

The absence of revenue generation underscores Enlivex's reliance on external funding, posing a risk to financial stability and limiting self-sufficiency until product commercialization.

Equity Decline

Declining stockholders' equity reflects financial instability, potentially limiting future strategic options and investor confidence in the company's long-term viability.

Enlivex Business Overview & Revenue Model

Company Description

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.

How the Company Makes Money

Enlivex generates revenue primarily through collaborations, partnerships, and licensing agreements related to its proprietary immunotherapy technologies. As a clinical-stage company, it does not yet have commercialized products generating direct sales revenue. Instead, its financial income is heavily reliant on funding from research grants, strategic alliances with pharmaceutical companies, and potential milestone payments or royalties from future successful commercialization of its therapies. Significant partnerships with established healthcare and pharmaceutical firms may also contribute to its earnings by providing financial support for clinical trials and research activities.

Enlivex Financial Statement Overview

Summary

Enlivex is facing challenges typical of early-stage biotechnology firms, with no revenue and ongoing losses. The firm needs to address its lack of revenue generation and improve cash flow management to ensure its financial viability. While the low debt offers some flexibility, the continuous cash burn and equity decline may limit future strategic options.

Income Statement

Enlivex has faced significant operational challenges with no reported revenue in recent periods, leading to negative gross and net margins. The consistent negative EBIT and EBITDA margins highlight ongoing profitability issues, with a lack of revenue growth exacerbating the financial strain.

Balance Sheet

The balance sheet reflects a relatively low debt-to-equity ratio, indicating limited leverage. However, the company's equity position has weakened over time as liabilities approach total assets, reducing the equity ratio. The declining stockholders' equity is a concern for financial stability.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, indicating operational inefficiencies and cash burn. Despite some cash inflows from financing activities, the company struggles to generate positive cash flow from operations, posing a risk to long-term sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	2.28M
Gross Profit	-292.00K	-545.00K	-835.00K	-777.00K	-546.00K	-286.00K
EBITDA	-13.67M	-14.47M	-28.22M	-25.02M	-18.74M	-9.50M
Net Income	-12.70M	-15.01M	-29.07M	-31.06M	-14.47M	-11.82M
Balance Sheet
Total Assets	20.94M	27.69M	36.83M	67.64M	95.15M	40.36M
Cash, Cash Equivalents and Short-Term Investments	18.32M	23.61M	27.32M	48.12M	84.13M	35.71M
Total Debt	701.00K	534.00K	1.03M	4.85M	617.00K	203.00K
Total Liabilities	3.46M	4.10M	6.75M	10.80M	10.11M	4.87M
Stockholders Equity	17.48M	23.59M	30.08M	56.84M	85.04M	35.49M
Cash Flow
Free Cash Flow	-12.33M	-13.11M	-23.76M	-32.08M	-19.17M	-12.03M
Operating Cash Flow	-12.23M	-13.01M	-23.52M	-23.95M	-17.54M	-11.01M
Investing Cash Flow	11.78M	9.06M	-25.97M	62.52M	-38.41M	-20.98M
Financing Cash Flow	1.83M	6.45M	360.00K	150.00K	60.98M	33.08M

Enlivex Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.97
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENLV, the sentiment is Neutral. The current price of 0.97 is above the 20-day moving average (MA) of 0.82, above the 50-day MA of 0.92, and below the 200-day MA of 1.05, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 59.09 is Neutral, neither overbought nor oversold. The STOCH value of 86.98 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ENLV.

Enlivex Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DARE	50 Neutral	$29.01M	-4.42	―	―	―	―
PASG	49 Neutral	$47.30M	-0.99	-87.18%	―	―	38.42%
CASI	46 Neutral	$15.80M	-0.33	―	―	26.20%	-42.26%
ENLV	45 Neutral	$229.43M	-1.75	-57.64%	―	―	46.09%
AKTX	42 Neutral	$8.72M	―	-196.60%	―	―	―

Enlivex Corporate Events

Enlivex Lists RAIN Treasury Token on KuCoin to Deepen Liquidity and Market Access

On January 7, 2026, Enlivex Therapeutics announced that its primary digital treasury asset, the RAIN token, began trading on the KuCoin cryptocurrency exchange effective January 6, 2026, providing access to one of the world’s largest digital asset trading platforms and significantly broadening the token’s potential user base, particularly in Southeast Asia. By securing a listing on a major global venue known for deep retail liquidity, Enlivex aims to enhance market access and secondary liquidity for its RAIN holdings, marking a key milestone in its digital asset treasury strategy and underscoring the company’s dual positioning at the intersection of late-stage osteoarthritis drug development and emerging decentralized finance infrastructure.

The most recent analyst rating on (ENLV) stock is a Hold with a $0.72 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.

Enlivex Calls February 2026 Extraordinary Meeting to Approve Governance Changes and Reverse Share Split

On December 18, 2025, Enlivex Therapeutics announced it will convene an Extraordinary General Meeting of Shareholders on February 3, 2026, at its offices in Ness Ziona, Israel, to seek investor approval for a series of significant corporate governance and capital structure changes. Shareholders will be asked to vote on amendments to the Articles of Association to change the company’s name to Enlivex Ltd. (or a similar name), introduce a classified board with three staggered director classes, and increase authorized share capital, as well as to approve updated exemption and indemnification agreements for directors and the CEO, an equity bonus in restricted share units for the executive chairman, and a reverse share split of ordinary shares at a ratio between 1-for-2 and 1-for-20 to be implemented within 12 months at the board’s discretion, moves that collectively signal a strategic effort to strengthen corporate defenses, enhance capital flexibility and address share price and listing considerations for stakeholders.

The most recent analyst rating on (ENLV) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.

Enlivex Announces Fireside Chat on RAIN Token and Allocetra Development

On December 4, 2025, Enlivex Therapeutics announced a virtual fireside chat scheduled for December 11, 2025, to discuss its digital asset strategy and the clinical development of Allocetra™. The company recently secured a $212 million private placement, which will support its strategic initiatives. This announcement highlights Enlivex’s efforts to strengthen its market position through innovative financial strategies and continued focus on addressing the significant healthcare burden of osteoarthritis.

The most recent analyst rating on (ENLV) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.

Enlivex Completes $212 Million Private Placement, Expands Digital Asset Strategy

On November 24, 2025, Enlivex Therapeutics Ltd. completed a $212 million private placement, marking a significant step in its strategic expansion into digital asset treasury operations through the RAIN token. The funds will support the company’s cryptocurrency treasury strategy and ongoing clinical development of Allocetra™. The appointment of Matteo Renzi, former Prime Minister of Italy, to the Board of Directors underscores Enlivex’s commitment to innovation and strategic leadership. Renzi’s expertise is expected to enhance the company’s positioning in both the biotech and digital asset sectors.

The most recent analyst rating on (ENLV) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.

Enlivex Reports Positive Six-Month Data for Knee Osteoarthritis Trial

Enlivex Therapeutics Ltd. announced positive six-month topline data from the Phase IIa stage of its Allocetra™ trial for moderate to severe knee osteoarthritis, reaffirming previous three-month results. The study demonstrated significant pain reduction and improved function in patients aged 60 and above, with sustained efficacy and a favorable safety profile, supporting further development and commercial potential.

The most recent analyst rating on (ENLV) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.

Enlivex Completes Private Placement to Fund Digital Asset Strategy

On November 24, 2025, Enlivex Therapeutics Ltd. announced the completion of a securities purchase agreement with accredited investors, resulting in a private placement of 212 million ordinary shares. The proceeds from this transaction will be used to implement a digital asset treasury strategy, primarily involving the acquisition of RAIN tokens and other digital assets. This move aims to support Enlivex’s operational needs and align its reserve management with the RAIN ecosystem development. The company has also entered into a Treasury Management Agreement with Elinnovation Labs Ltd. to manage these assets, highlighting a strategic shift towards cryptocurrency and digital asset management, which carries inherent risks due to market volatility and regulatory uncertainties.

The most recent analyst rating on (ENLV) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.

Enlivex Reports Q3 2025 Financial Results Amidst Operational Challenges

Enlivex Therapeutics Ltd. released its unaudited condensed consolidated financial statements for the periods ending September 30, 2025, and 2024. The financial report highlights a decrease in total assets from $27.7 million at the end of 2024 to $20.9 million by September 2025, alongside a net loss of $7.5 million for the nine months ending September 2025. This financial performance reflects ongoing challenges in the company’s operations, potentially impacting its market position and stakeholder confidence.

The most recent analyst rating on (ENLV) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.

Enlivex Reschedules Annual Meeting Due to Lack of Quorum

On November 10, 2025, Enlivex Therapeutics Ltd. attempted to hold its Annual General Meeting of Shareholders but had to adjourn due to a lack of quorum. The meeting is rescheduled for November 17, 2025, with extended deadlines for shareholder voting, reflecting the company’s commitment to ensuring shareholder participation and governance compliance.

The most recent analyst rating on (ENLV) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.